Claire C.
- Country
- France
- Department
- Service de Néphrologie et de Médecine Interne
Research Overview
- Phase III Randomized Double‑Blind Placebo‑Controlled Trial of Elecoglipron (AZD5004) on Renal Decline and Mortality in Adults with Chronic Kidney Disease
- Phase 3 Randomized Double-Blind Placebo-Controlled Trial of Povetacicept in Adults with Immunoglobulin A Nephropathy
- Evaluation of Immunosuppressive Therapy Discontinuation Versus Maintenance in ANCA-Associated Vasculitis with End-Stage Renal Disease: A Randomized Multicenter Trial
Data & Insights
Has run more than one trial at 61 of 343 partner sites.
Specializations
Glomerular Disorders
This investigator specializes in treating various forms of glomerulonephritis, with particular emphasis on minimal change nephrotic syndrome and membranous nephropathy. Their research explores innovative therapeutic approaches using rituximab and personalized medicine protocols.
- Minimal Change Disease Treatment
- Membranous Nephropathy Management
- Artificial Intelligence in Treatment Protocols
IgA Nephropathy Research
The investigator has extensive involvement in IgA nephropathy treatment studies, investigating multiple therapeutic agents including atrasentan, povetacicept, and hydroxychloroquine. Their work focuses on preventing progressive renal function loss and reducing proteinuria.
- Novel Therapeutic Approaches
- Proteinuria Management
- Renal Function Preservation
Complex Renal Conditions
Their expertise extends to managing severe renal conditions including ANCA vasculitis and focal segmental glomerulosclerosis. The investigator studies immunosuppressive therapy strategies and novel treatments like sparsentan for these challenging conditions.
- ANCA Vasculitis Management
- End-stage Renal Disease
- FSGS Treatment Innovation
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.